Novadip Biosciences
PrivateLast Round
Convertible Debt
Sep 21, 2026
Total Funding Raised
$108.54M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Novadip Biosciences is a biotechnology company that develops regenerative tissue products to accelerate healing for large bone defects, bone non-union, and spine fusion.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Novadip Biosciences Comparables
Compare Novadip Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EpiBone | 86% | |
| Bonus Biogroup | 78% | |
| Theradaptive | 78% |
Novadip Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Sep 21, 2026 | ||||
| Debt | Dec 14, 2023 | ||||
| Series B Extension | Nov 3, 2022 | ||||
| Series B | Oct 28, 2021 | ||||
| Series A | Sep 10, 2015 |
Key People
Founding team and executive leadership
Novadip Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Series A |
| Sopartec | Convertible Debt, Series B, Series A, Series B Extension |
| Noshaq | Convertible Debt |
| Epimede | Series A |
| Fund+ | Convertible Debt, Series A, Series B, Series B Extension |
| Société Régionale d'Investissement de Wallonie | Series A |
| Investsud | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 21, 2026
$12M round led by New Science Ventures
- Aug 21, 2026
Monthly visitors grew 110% MoM, from 3.6K to 7.6K.
Recent news
Latest coverage and updates
- receives_financingSep 21, 2026
Novadip received financing of $11.9M in convertible financing round on Sep 21st '26.
- is_developingSep 21, 2026
Novadip is developing NVD003, an autologous cell-based therapy, in the United States and EU on Sep 21st '26
Novadip Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Novadip Biosciences's valuation, stock price, and market status.
Is Novadip Biosciences a public or private company?
Novadip Biosciences is a private company.
What is the current stock price of Novadip Biosciences?
Novadip Biosciences is a private company, so its shares have no public market price. Caplight tracks Novadip Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Novadip Biosciences worth (valuation)?
Valuation information for Novadip Biosciences is not publicly available.
Can I buy Novadip Biosciences stock?
Novadip Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Novadip Biosciences's last funding round?
Novadip Biosciences's most recent funding round was Convertible Debt on September 21, 2026.
Who are the main investors in Novadip Biosciences?
Key investors in Novadip Biosciences include Fund+, European Investment Bank Group, New Science Ventures.
Will Novadip Biosciences IPO soon?
No public IPO plans have been announced for Novadip Biosciences.
How can I track Novadip Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Novadip Biosciences's shares on secondary markets.